Seven domestic new crown vaccines are being accepted by WHO's emergency use list. Experts call on China's vaccine industry to accelerate the process of internationalization

Recently, the Global Health Innovation Center of Duke University in the United States released the "New Coronary Pneumonia Vaccine Market Launch and Scale Speedometer (The Launch and Scale Speedometer)".

While this brings severe challenges to the world vaccine industry, including China, it also allows the world to see infinite opportunities brought about by international cooperation.

The current global supply of new crown vaccines is obviously insufficient, and the global distribution of new crown vaccines has appeared unequal.

In response to this inequality, “China's new crown vaccine is being used as a global public product to contribute to the realization of the accessibility and affordability of vaccines in developing countries.

Feng Duojia, president of the China Vaccine Industry Association, said that up to now, the domestic use of my country's domestic new crown vaccine has exceeded 130 million doses, and the number of exports has exceeded 100 million doses, which are basically the same.

"China's vaccine has long-term responsibility to provide global public products and services.

With the help of the World Health Organization's Emergency Use List (WHO EUL) program, China's new crown vaccine has obtained a platform to provide international services.

On October 8, 2020, China signed an agreement with the Global Alliance for Vaccines and Immunization to formally join the "New Coronary Pneumonia Vaccine Implementation Plan" (COVAX), upholding the concept of a community of human health and fulfilling its own commitments to promote vaccines as global public products.

"China's vaccine industry is very active and is actively contributing to world public health.

"China's vaccines are accelerating the historic transformation from a major vaccine country to a powerful vaccine country in terms of quality and production.

So, how should the Chinese vaccine industry accelerate the process of internationalization and achieve "excellent" and "strong"? In Feng Duojia's view, "excellent" means that the whole process and all elements of vaccine products and services are in line with international standards; "strong" means having a strong vaccine industry capability and production efficiency.

Dong Jian, CEO of WuXi Hyde and Senior Vice President of WuXi Biologics, also said that ensuring service quality, ensuring production scale and cost control will help Chinese companies enter the international market.